PRIMARY RESULTS OF A PHASE 1 MULTICENTER OPEN-LABEL STUDY OF ANTOLIMAB, AN ANTI-SIGLEC-8 ANTIBODY, FOR THE TREATMENT OF PATIENTS WITH CHRONIC GASTROINTESTINAL SYMPTOMS AND ELEVATED GASTRIC AND/OR DUODENAL MAST CELLS

antolimab (AK002) - Allakos

https://ddw.apprisor.org/epsSearchDDW.cfm

Adam C. Bledsoe2; Sabine Hazan3; Robert M. Genta4; Gary W. Falk5; Kenneth Boren6; Kathryn A. Peterson7; Malika Pasha1; Bhupinder Singh1; Alan T. Chang1; Amol P. Kamboj1; Henrik S. Rasmussen1; Ikuo Hirano8; Evan S. Dellon9

May 4, 2020